Genolim

Genolim is a South Korean biotechnology company specializing in the development of next-generation gene therapies using adeno-associated virus (AAV) vectors. The company focuses on addressing unmet medical needs in ophthalmic and central nervous system (CNS) disorders. Its lead program, GL-101, is a gene therapy candidate designed for the long-term treatment of wet age-related macular degeneration (wAMD) by delivering anti-VEGF agents. Genolim leverages its proprietary platform to optimize vector design and enhance therapeutic efficacy. The company aims to transition from traditional frequent injections to a "one-and-done" treatment paradigm for chronic diseases. Founded by experts in vascular biology, the firm is currently advancing its pipeline through pre-clinical validation.